已发表论文

ROMA 指数在卵巢癌诊断中的临床价值:荟萃分析

 

Authors Cui RL, Wang YC, Li Y, Li YG

Received 24 December 2018

Accepted for publication 4 February 2019

Published 28 March 2019 Volume 2019:11 Pages 2545—2551

DOI https://doi.org/10.2147/CMAR.S199400

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Professor Lu-Zhe Sun

Objectives: The role of retrospective analysis has evolved greatly in cancer research. We undertook this network meta-analysis to evaluate retrospectively the diagnostic value of ROMA in ovarian cancer. 
Materials and methods: We systematically retrieved 56 relevant articles published about ROMA index from 2009–2018 and about ovarian cancer from China National Knowledge Infrastructure (CNKI), PubMed and EMBASE. Data were comprehensively analyzed by RevMan 5.3 and MetaDisc 12.4 software.
Results: Data of 5,954 cases were retrieved from 23 literatures. Among them, 2,117 cases were in the ovarian cancer group and 3,837 cases in the control group. The pooled estimates for the ROMA index were sensitivity: 0.90 (95% CI: 0.88–0.93), specificity: 0.91 (95% CI: 0.89–0.94), positive predictive: 0.90 (95% CI: 0.88–0.95), negative predictive: 0.93 (95% CI: 0.91–0.95), and area under ROC curve: 0.96, compared to 0.71 (95% CI: 0.56–0.82), 0.87 (95% CI: 0.80–0.92), 0.82 (95% CI: 0.78–0.86), 0.92 (95% CI: 0.90–0.94), and 0.88 of HE4, respectively.
Conclusions: This meta-analysis confirms that the risk of ovarian malignancy algorithm can facilitate the diagnosis of ovarian cancer to some extent.
Keywords: ROMA index, ovarian cancers, meta-analysis




Figure 5 Area under ROC curve (AUC) of the ROMA index for...